Cargando…
Two years later, azithromycin for COVID-19 and the effect on the heart, is it still relevant?
Autor principal: | Matoso Laranjo, Sérgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021043/ https://www.ncbi.nlm.nih.gov/pubmed/35469294 http://dx.doi.org/10.1016/j.repc.2022.04.005 |
Ejemplares similares
-
Azithromycin for severe COVID-19
por: Oldenburg, Catherine E, et al.
Publicado: (2020) -
Azithromycin: can its benefit be ruled out in mild COVID-19?
por: Rodríguez-Molinero, Alejandro
Publicado: (2021) -
Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019) -
Chatbots in the fight against the COVID-19 pandemic
por: Miner, Adam S., et al.
Publicado: (2020) -
Is nanomedicine still promising?
por: Peiris, Pubudu M., et al.
Publicado: (2011)